TABLE 2

Prediction of Clinical Response of Metastatic Breast Cancer by Relative or Absolute Changes in 18F-FDG Uptake on 18F-FDG PET

Tumor type or stageAuthorsYearNo. of patientsPET timingPET criterionOutcome measureDesignPET performanceResponse rate
Bone-dominant metastatic breast cancerSpecht et al. (49)200728During treatmentNo change in SUV (vs. 42% decrease)Disease progressionRetrospectiveHazard ratio, 2.2 (P = 0.006)13/28 (46%)*
Metastatic breast cancerDose Schwarz et al. (50)200511After first cycleVisual analysisClinical responseProspectiveAccuracy, 100%6/11 (55%)
After first cycleRelative decrease in SUVClinical response28% vs. 6% (P = 0.02)§
After second cycleRelative decrease in SUVClinical response46% vs. 21% (P = 0.003)§
Metastatic breast cancerGennari et al. (48)20009After first cycleAbsolute decrease in SUVClinical or radiographic responseProspectiveSUV decrease from 7.7 to 5.76/9 (67%)
  • * Response was defined as no progression of bone metastases during median follow-up time of 17.5 mo.

  • Clinical response based on changes in tumor size assessed by conventional imaging.

  • Clinical or radiographic response.

  • § Relative decrease in SUV in patients showing clinical response vs. nonresponders.

  • Absolute decrease in SUV in patients showing clinical response vs. no change in nonresponders.